Orkide Kutlu1, Özgür Altun1, Okan Dikker2, Şerife Aktaş3, Neslihan Özsoy1, Yücel Arman1, Eylem Özgün Çil1, Mustafa Özcan1, Şengül Aydın Yoldemir1, Murat Akarsu1, İlkim Deniz Toprak1, Kerem Kırna4, Yasin Kutlu1, Zeki Toprak5, Hasan Eruzun6, Tufan Tükek7. 1. Internal Medicine Department, Okmeydanı Training and Research Hospital, Istanbul, Turkey. 2. Medical Biochemistry Department, Okmeydanı Training and Research Hospital, Istanbul, Turkey. 3. Internal Medicine Department, Umraniye Training and Research Hospital, Istanbul, Turkey. 4. Internal Medicine Department, Haseki Training and Research Hospital, Istanbul, Turkey. 5. Nephrology Department, Bakırkoy Dr. Sadı Konuk Training and Research Hospital, Istanbul, Turkey. 6. Internal Medicine Department, Okmeydanı Training and Research Hospital, Istanbul, Turkey, hasaneruzun@gmail.com. 7. Internal Medicine Department, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Abstract
OBJECTIVES: Adropin is a novel marker of metabolic syndrome and insulin resistance. The aim of this study was to explore the association of serum adropin levels with hepatosteatosis among adult patients. MATERIALS AND METHODS: Serum biochemical parameters including liver and renal function tests, insulin levels, and serum adropin levels were compared between adult patients with nonalcoholic fatty liver disease (NAFLD) and healthy control cases. RESULTS: A total of 51 patients with a mean age of 37.9 ± 9.96 years diagnosed with grade 2-3 hepatosteatosis and 30 healthy control cases with a mean age of 34.8 ± 9.5 years were included in the study. Serum adropin levels in the NAFLD group were statistically significantly lower than in the control cases (588.4 ± 261.0 vs. 894.2 ± 301.2, respectively; p < 0.001). The study participants were further subdivided into 2 groups as patients with (n = 35) or without (n = 46) insulin resistance using the serum homeostatic model of assessment-insulin resistance (HOMA-IR). Serum adropin levels were statistically significantly lower in patients with insulin resistance (p < 0.01). There was a negative correlation between adropin levels and serum insulin, HOMA-IR, urea, gamma-glutamyl transferase, total cholesterol, and triglyceride levels. CONCLUSION: We observed a decrease in serum adropin levels among adult patients with NAFLD. We also found lower levels of serum adropin in patients with insulin resistance, supporting previous data in the literature. Studies investigating the association of adropin levels with other inflammatory parameters are warranted to define its exact role in the pathogenesis of hepatosteatosis.
OBJECTIVES:Adropin is a novel marker of metabolic syndrome and insulin resistance. The aim of this study was to explore the association of serum adropin levels with hepatosteatosis among adult patients. MATERIALS AND METHODS: Serum biochemical parameters including liver and renal function tests, insulin levels, and serum adropin levels were compared between adult patients with nonalcoholic fatty liver disease (NAFLD) and healthy control cases. RESULTS: A total of 51 patients with a mean age of 37.9 ± 9.96 years diagnosed with grade 2-3 hepatosteatosis and 30 healthy control cases with a mean age of 34.8 ± 9.5 years were included in the study. Serum adropin levels in the NAFLD group were statistically significantly lower than in the control cases (588.4 ± 261.0 vs. 894.2 ± 301.2, respectively; p < 0.001). The study participants were further subdivided into 2 groups as patients with (n = 35) or without (n = 46) insulin resistance using the serum homeostatic model of assessment-insulin resistance (HOMA-IR). Serum adropin levels were statistically significantly lower in patients with insulin resistance (p < 0.01). There was a negative correlation between adropin levels and serum insulin, HOMA-IR, urea, gamma-glutamyl transferase, total cholesterol, and triglyceride levels. CONCLUSION: We observed a decrease in serum adropin levels among adult patients with NAFLD. We also found lower levels of serum adropin in patients with insulin resistance, supporting previous data in the literature. Studies investigating the association of adropin levels with other inflammatory parameters are warranted to define its exact role in the pathogenesis of hepatosteatosis.
Authors: Andrew A Butler; Charmaine S Tam; Kimber L Stanhope; Bruce M Wolfe; Mohamed R Ali; Majella O'Keeffe; Marie-Pierre St-Onge; Eric Ravussin; Peter J Havel Journal: J Clin Endocrinol Metab Date: 2012-08-07 Impact factor: 5.958
Authors: Christopher D Williams; Joel Stengel; Michael I Asike; Dawn M Torres; Janet Shaw; Maricela Contreras; Cristy L Landt; Stephen A Harrison Journal: Gastroenterology Date: 2010-09-19 Impact factor: 22.682
Authors: Su Gao; Ryan P McMillan; Qingzhang Zhu; Gary D Lopaschuk; Matthew W Hulver; Andrew A Butler Journal: Mol Metab Date: 2015-01-17 Impact factor: 7.422
Authors: Mehmet Akif Erdol; Seyma Ertem; Ahmet Goktug Ertem; Koray Demirtas; Sefa Unal; Mustafa Karanfil; Ahmet Akdi; Cagri Yayla Journal: Med Princ Pract Date: 2019-07-11 Impact factor: 1.927
Authors: Mariami Jasaszwili; Maria Billert; Mathias Z Strowski; Krzysztof W Nowak; Marek Skrzypski Journal: Molecules Date: 2020-01-27 Impact factor: 4.411
Authors: Mahmoud Mustafa Ali Abulmeaty; Ali Madi Almajwal; Khalid S Alnumair; Suhail Razak; Mai Mohammed Hasan; Amal Fawzy; Abdullah Ibrahim Farraj; Manal Abudawood; Ghadeer S Aljuraiban Journal: Biology (Basel) Date: 2021-05-07